Table 3.
Author of the Study | Year of Publication | Number of Patients | Age of Patients | Dose | Positive Response to the Treatment | Adverse Effects |
---|---|---|---|---|---|---|
Tarquinio D et al. [40] | 2022 | 163 | 12–17 | 0.3 mg/kg | 143 (88%) | fever (17.9%), upper respiratory tract infection (17.9%), nosebleeds (2.6%) |
Kay L et al. [44] | 2019 | 42 | 5–92 | 2.5–15 mg/kg | 24 (57.1%) | nasal irritation (11.9%) |